Fractyl Health Faces Class Action Lawsuit Over Clinical Study Disclosures

The complaint, filed in the U.S. District Court for the Southern District of New York, represents investors who purchased Fractyl securities between January 13, 2025, and January 29, 2026. Plaintiffs allege that during this period, the company touted the Revita system—an outpatient procedure designed to treat duodenal dysfunction—as a breakthrough for weight maintenance. These optimistic claims reportedly facilitated public stock offerings that generated tens of millions of dollars for the firm.

Legal trouble emerged on January 29, 2026, when Fractyl disclosed that six-month data from its REMAIN-1 Midpoint Cohort showed more modest results than previously indicated. CEO Harith Rajagopalan attributed the shortfall to operational issues at a single clinical site, where inadequate diet and lifestyle counseling programs skewed the data. The market reacted sharply; Fractyl’s stock dropped over 68% on the day of the announcement and continued to slide following subsequent analyst downgrades from firms like Morgan Stanley, which slashed its price target from $8.00 to $2.00.

Investors seeking to participate as lead plaintiffs must petition the court by October 20, 2026. The lawsuit centers on allegations that Fractyl violated federal securities laws under the Securities Exchange Act of 1934 by concealing the compromised integrity of its clinical trials while maintaining a positive public narrative.